Molly Jung, Mark H. Kuniholm, Gloria Y.F. Ho, Scott Cotler, Howard D. Strickler, Bharat Thyagarajan, Marston Youngblood, Robert C. Kaplan, Julia del Amo – 2 November 2015 – Little is known regarding the prevalence and distribution of hepatitis B virus (HBV) infection in U.S. Hispanics/Latinos. We sought to determine the prevalence of HBV exposure (serum HBV core antibody; anti‐HBc), active HBV infection (serum HBV surface antigen; HBsAg), and vaccine‐induced HBV immunity (antibody against HBV surface antigen; anti‐HBs) in U.S.

Abhinav Vasudevan, Zaid Ardalan, Paul Gow, Peter Angus, Adam Testro – 2 November 2015

Giacomo Lanzoni, Vincenzo Cardinale, Guido Carpino – 2 November 2015 – Stem/progenitors for liver, biliary tree, and pancreas exist at early stages of development in the definitive ventral endoderm forming the foregut. In humans, they persist postnatally as part of a network, with evidence supporting their contributions to hepatic and pancreatic organogenesis throughout life. Multiple stem cell niches persist in specific anatomical locations within the human biliary tree and pancreatic ducts.

Marta Cavallin, Salvatore Piano, Paolo Angeli – 2 November 2015

Alexis P. Chidi, Shari Rogal, Cindy L. Bryce, Michael J. Fine, Chester B. Good, Larissa Myaskovsky, Vinod K. Rustgi, Allan Tsung, Kenneth J. Smith – 2 November 2015 – Recently approved, interferon‐free medication regimens for treating hepatitis C are highly effective, but extremely costly. We aimed to identify cost‐effective strategies for managing treatment‐naïve U.S. veterans with new hepatitis C medication regimens. We developed a Markov model with 1‐year cycle length for a cohort of 60‐year‐old veterans with untreated genotype 1 hepatitis C seeking treatment in a typical year.

Robert S. Brown, Jacqueline G. O'Leary, K. Rajender Reddy, Alexander Kuo, Giuseppe J. Morelli, James R. Burton, R. Todd Stravitz, Christine Durand, Adrian M. Bisceglie, Paul Kwo, Catherine T. Frenette, Thomas G. Stewart, David R. Nelson, Michael W. Fried, Norah A. Terrault, on behalf of the Hepatitis C Therapeutic Registry Research Network Study Group – 31 October 2015 – Recurrent infection with the hepatitis C virus (HCV) after liver transplantation (LT) is associated with decreased graft and patient survival.

Seong Yeon Park, Ki‐Ho Park, Oh‐Hyun Cho, Yu‐Mi Lee, Sang‐Ho Choi, Mi Suk Lee – 30 October 2015

Mattias Ekstedt, Hannes Hagström, Patrik Nasr, Mats Fredrikson, Per Stal, Stergios Kechagias, Rolf Hultcrantz – 30 October 2015

Maria Antonella Burza, Benedetta Maria Motta, Rosellina Margherita Mancina, Piero Pingitore, Carlo Pirazzi, Saverio Massimo Lepore, Rocco Spagnuolo, Patrizia Doldo, Cristina Russo, Veronica Lazzaro, Janett Fischer, Thomas Berg, Alessio Aghemo, Cristina Cheroni, Raffaele De Francesco, Silvia Fargion, Massimo Colombo, Christian Datz, Felix Stickel, Luca Valenti, Stefano Romeo – 30 October 2015 – Chronic hepatitis C virus (HCV) infection may progress to cirrhosis and hepatocellular carcinoma (HCC).

Einar S. Björnsson, Jay H. Hoofnagle – 30 October 2015 – An important element in assessing causality in drug‐induced liver injury is whether the implicated agent is known to cause hepatotoxicity. We classified drugs into categories based on the number of published reports of convincingly documented, clinically apparent, idiosyncratic liver injury. Drugs described in the website LiverTox (http://livertox.nih.gov) were classified into five categories based on the number of published cases (category A, ≥50; category B, 12‐49; category C, 4‐11; category D, 1‐3; category E, none).